A comparative study between cryo-laser cryo-sclerotherapy and sclerotherapy in the treatment of telangiectasia and reticular veins: A randomized controlled trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101607771 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-3348 (Electronic) Linking ISSN: 2213333X NLM ISO Abbreviation: J Vasc Surg Venous Lymphat Disord Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Elsevier Inc., c2013-
    • Subject Terms:
      Telangiectasis*/therapy ; Sclerotherapy*/adverse effects ; Sclerotherapy*/methods ; Sclerosing Solutions*/administration & dosage ; Sclerosing Solutions*/adverse effects ; Polidocanol*/administration & dosage ; Polidocanol*/therapeutic use; Humans ; Female ; Male ; Adult ; Middle Aged ; Treatment Outcome ; Prospective Studies ; Cryosurgery/adverse effects ; Polyethylene Glycols/administration & dosage ; Glucose/administration & dosage ; Veins/diagnostic imaging ; Feasibility Studies ; Laser Therapy/adverse effects ; Young Adult ; Aged ; Time Factors
    • Abstract:
      Objective: Telangiectasias, characterized by dilated venules, are frequently observed in the lower extremities. Sclerotherapy stands out as the predominant treatment of these vascular lesions. The integration of laser therapy with a mild sclerosing agent, serving as an osmotic sclerosant, presents an enhanced cosmetic treatment approach, aiming to optimize outcomes and minimize potential adverse effects. This study sought to evaluate the feasibility, efficacy, and safety of cryo-laser and cryo-sclerotherapy (CLaCS) and compare it with injection sclerotherapy for the treatment of telangiectasia and reticular veins.
      Methods: In this randomized controlled trial, individuals expressing concerns about telangiectasia and reticular veins were recruited for aesthetic treatment. The enrolled patients were prospectively randomized according to the chosen treatment technique. Group A included patients undergoing CLaCS with 70% dextrose, focusing on a single area measuring 20 cm by 20 cm. Group B included patients receiving polidocanol injection sclerotherapy for a single area of the same dimensions.
      Results: Group A comprised 195 patients and group B comprised 197 patients. The rates of complete lesion elimination after the first, second, and third treatment sessions were 64.6%, 86.2%, and 100% in group A and 50.3%, 74.1%, and 85.3% in group B, respectively. Group A exhibited a significantly higher complete elimination rate compared with group B at the conclusion of the study (P < .001). Furthermore, group A demonstrated a statistically significant lower incidence of postprocedural pigmentation and other complications compared with group B (P < .001). These findings underscore the enhanced efficacy and safety profile associated with the CLaCS technique using 70% dextrose compared with injection sclerotherapy with polidocanol.
      Conclusions: CLaCS, combining cryo-laser and cryo-sclerotherapy, demonstrated superior efficacy and safety compared with traditional polidocanol sclerotherapy for treating telangiectasia and reticular veins.
      Competing Interests: Disclosures None.
      (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
    • References:
      Cochrane Database Syst Rev. 2021 Dec 10;12:CD001732. (PMID: 34883526)
      Lasers Med Sci. 2014 Mar;29(2):481-92. (PMID: 24220848)
      Phlebology. 2023 Apr;38(3):165-171. (PMID: 36657386)
      Dermatol Surg. 2012 Aug;38(8):1322-30. (PMID: 22620717)
      Cochrane Database Syst Rev. 2021 Oct 12;10:CD012723. (PMID: 34637138)
      Cochrane Database Syst Rev. 2011 Dec 07;(12):CD008826. (PMID: 22161437)
      Dermatol Surg. 2004 Mar;30(3):367-72; discussion 372. (PMID: 15008862)
      J Clin Med. 2021 Jul 22;10(15):. (PMID: 34362022)
      J Eur Acad Dermatol Venereol. 2015 Mar;29(3):549-54. (PMID: 25069999)
      Phlebology. 2012 Jun;27(4):184-90. (PMID: 22045827)
      Dermatol Surg. 2002 Jan;28(1):52-5. (PMID: 11991271)
      Dermatol Surg. 2005 Jun;31(6):631-5; discussion 635. (PMID: 15996411)
      Int J Mol Sci. 2013 Jun 07;14(6):12222-48. (PMID: 23749111)
      Semin Intervent Radiol. 2005 Sep;22(3):209-17. (PMID: 21326695)
      Phlebology. 2014 Dec;29(10):658-66. (PMID: 23989971)
      Phlebology. 2019 Sep;34(1 Suppl):4-66. (PMID: 31495256)
      J Vasc Surg Venous Lymphat Disord. 2020 Sep;8(5):893-895. (PMID: 32179040)
      Curr Cardiol Rep. 2019 Aug 30;21(10):114. (PMID: 31471728)
      Dermatol Surg. 2011 Nov;37(11):1590-4. (PMID: 21883648)
      J Vasc Bras. 2018 Oct-Dec;17(4):341-347. (PMID: 30787955)
      Aesthet Surg J. 2015 Sep;35(7):NP221-9. (PMID: 26246022)
      Eur J Vasc Endovasc Surg. 2022 Feb;63(2):184-267. (PMID: 35027279)
    • Contributed Indexing:
      Keywords: CLaCS; Cryo-laser cryo-sclerotherapy; Dextrose 70%; Injection sclerotherapy; Polidocanol; Telangiectasias and reticular veins
    • Accession Number:
      0 (Sclerosing Solutions)
      0AWH8BFG9A (Polidocanol)
      3WJQ0SDW1A (Polyethylene Glycols)
      IY9XDZ35W2 (Glucose)
    • Publication Date:
      Date Created: 20240324 Date Completed: 20240620 Latest Revision: 20241101
    • Publication Date:
      20241101
    • Accession Number:
      PMC11523426
    • Accession Number:
      10.1016/j.jvsv.2024.101874
    • Accession Number:
      38522666